OrbiMed’s VistaGen Therapeutics VTGN Stock Holding History

OrbiMed’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Hold	3,060,000	–	–	0.03%	109
2025 Q4	$2.03M	Hold	3,060,000	–	–	0.04%	100
2025 Q3	$10.9M	Buy	+3,060,000	New	+$9.14M	0.26%	73
2022 Q3	–	Sell	-447,376	Closed	-$11.8K	–	147
2022 Q2	$11.8K	Buy	447,376 +17,067	+4%	+$603K	0.21%	84
2022 Q1	$16M	Hold	430,309	–	–	0.26%	77
2021 Q4	$25.2M	Hold	430,309	–	–	0.32%	75
2021 Q3	$35.4M	Sell	430,309 -51,953	-11%	-$4.51M	0.39%	70
2021 Q2	$45.6M	Buy	482,262 +195,462	+68%	+$14.5M	0.46%	61
2021 Q1	$18.3M	Buy	286,800 +36,800	+15%	+$2.46M	0.17%	103
2020 Q4	$14.6M	Buy	+250,000	New	+$6.38M	0.13%	113

Other funds holding VTGN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

OrbiMed's VTGN Position: Q1 2026 in Review

OrbiMed held its VistaGen Therapeutics (VTGN) position steady in Q1 2026 at 3,060,000 shares worth $1.75M. The position accounts for 0.03% of the portfolio, ranked #109.

OrbiMed first reported a position in VTGN in Q4 2020 and has held it in 10 quarters since. The position peaked at $45.6M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

OrbiMed held 3,060,000 shares of VistaGen Therapeutics worth $1.75M as of Q1 2026.
OrbiMed left its VistaGen Therapeutics share count unchanged in Q1 2026.
VistaGen Therapeutics made up 0.03% of OrbiMed's portfolio in Q1 2026, its #109 holding.
OrbiMed first reported a position in VistaGen Therapeutics in Q4 2020 and has held it in 10 quarters since.
OrbiMed's VistaGen Therapeutics position peaked at $45.6M in Q2 2021.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.